Q4 2023
Released Mar 7, 2024, after the close
10-K filed Mar 15, 2024, 75 days after period end · 0001493152-24-010107
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.25M$3.25M derived+27.3% vs Q4 2022−13.0% vs Q3 2023
Net Income-$654.00K-$654.00K derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$2,021,000+32.9%
Operating Incomederived-$649,000N/M
Operating Cash Flowderived-$237,000N/M
Margins · derived
Gross margin62.1%+2.6 pt vs Q4 2022
Operating margin-19.9%+7.2 pt vs Q4 2022
Net margin-20.1%+10.1 pt vs Q4 2022
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $3.25M | $2.56M | $2.64M | $2.33M |
| Net Income | -$654.00K | -$771.00K | -$982.00K | -$759.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR